Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 309 | 1,176 | 1,416 | 2,459 | 3,810 | 5,351 | 6,123 | 6,744 |
| Operating profit | $m | 448 | 922 | ||||||
| Net profit | $m | -1,625 | -1,458 | -2,004 | -882 | -645 | 287 | 655 | 824 |
| EPS reported | $ | 0.20 | 0.44 | ||||||
| Operating cashflow per share | $ | 0.80 | 1.03 | ||||||
| Capex per share | $ | 0.13 | 0.12 | ||||||
| FCF per share | $ | 0.67 | 0.91 | ||||||
| Free cash flow | $m | 943 | 1,313 | ||||||
| Net debt | $m | -3,569 | -4,025 | ||||||
| Book value equity | $m | 4,361 | 5,174 | ||||||
| Book value per share | $ | 2.96 | 3.44 | ||||||
| Number of shares | m | 1,474.83 | 1,505.36 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 115.16 | 63.64 | ||||||
| P/B LTM | x | 7.49 | 7.17 | ||||||
| P/S LTM | x | 6.10 | 6.06 | ||||||
| P/FCF LTM | x | 34.63 | 28.24 | ||||||
| EV/EBITDA LTM | x | 49.45 | 29.94 | ||||||
| EV/Sales LTM | x | 5.45 | 5.40 | ||||||
| Earnings Yield LTM | % | 0.87% | 1.57% | ||||||
| FCF Yield | % | 2.89% | 3.54% | ||||||
| Quality | |||||||||
| ROE | % | 6.59% | 14.22% | ||||||
| ROIC | % | 4.76% | 9.58% | ||||||
| Operating margin | % | 8.37% | 15.06% | ||||||
| Gross margin | % | 85.28% | 87.82% | ||||||
| FCF/Sales | % | 17.63% | 21.44% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +40.44% | +34.22% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | +696.52% | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.86 | 1.15 | ||||||
| Net Debt/EBITDA | x | -5.93 | -3.58 | ||||||
| EBIT/Net interest | x | 7.68 | 9.91 | ||||||
| Net debt/market cap | % | -10.93% | -10.85% | ||||||
| Net debt/Equity | x | -0.82 | -0.78 | ||||||
| Gross debt/equity | x | 0.25 | 0.22 | ||||||
ETFs that hold BeOne Medicines
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| KraneShares MSCI All China Health Care Index ETF | KURE | 2 | 8.45% |
Funds with BeOne Medicines among their ten largest holdings, largest fund first.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| KraneShares MSCI All China Health Care Index ETF | KURE | 2 | 8.45% |
Funds with BeOne Medicines among their ten largest holdings, largest fund first.
Based on consensus from external analysts. Not Kvantra's opinion.
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free